CION Ameerpet
Most second opinions end by confirming the plan you already have — and that confirmation is worth something on its own. The value of a review lies in when you ask for it, because there are a few points in the ovarian cancer pathway where a fresh reading genuinely changes what happens next, and the largest of them comes before any operation.
Usually it confirms what you already have. That is the honest starting point, and it is worth saying before anything else, because women arrive at an ovarian cancer second opinion braced for a fight and half-expecting to be told everything so far was wrong. Far more often, a reviewer reads the file and agrees with it. Hearing that from someone with no stake in the first plan is not a wasted afternoon — it is often the first time since the diagnosis that a woman stops second-guessing herself.
The question that actually matters is not whether to get a review but when. Ovarian cancer is treated as a sequence, and each step narrows the choices in the step after it. An opinion sought before the first operation can change the operation. The same opinion sought six weeks later can only comment on it. That is the single most useful thing to understand about second opinions in this disease.
This page is about telling those moments apart: the points where a review changes management, the points where it mostly buys confidence, and what to put in front of a reviewer so the hour is not spent chasing missing paperwork. For the disease itself, start with our complete guide to ovarian cancer.
Most reviews confirm the plan. That closes the loop on the doubt that follows a cancer diagnosis, and it lets a woman commit to treatment instead of hesitating through it.
A review before surgery, or before maintenance starts, can still change the decision. The same review afterwards can only explain what was done.
Asking for an opinion does not commit you to changing hospitals, doctors or anything else. Many women go back to their original team with the plan confirmed.
The NCCN Ovarian Cancer guidelines state that a woman with a suspected ovarian, fallopian tube or primary peritoneal cancer should be evaluated by a gynaecologic oncologist before surgery, and they treat expert review of pathology and imaging as a normal part of the work-up rather than as a challenge to anyone. The reason is mechanical: how completely disease is removed at the first operation is one of the strongest determinants of what the rest of treatment can achieve, and that first operation cannot be repeated. It is also why the surgical decision — operate first, or give chemotherapy first — is the point at which a second opinion carries the most weight. Source: NCCN Clinical Practice Guidelines in Oncology — Ovarian Cancer / Fallopian Tube Cancer / Primary Peritoneal Cancer.
Not every stage of treatment is equally open to revision. These are the points where a fresh reading of the same file can still change what happens next — roughly in the order they arise.
This is the highest-value moment, and the one most often missed. Two questions are decided here: who operates, and whether to operate first at all. Guidelines are clear that a suspected ovarian cancer should be assessed by a gynaecologic oncologist before the operating list is booked, because staging and cytoreduction are specialist procedures rather than general gynaecological ones.
The second question is sequencing. Where disease is widespread, or where a woman is not fit for a long operation, chemotherapy first followed by an interval operation is an established alternative to operating immediately — not a lesser option. If nobody has explained why your plan goes one way rather than the other, that is a fair thing to ask about. Our guide to neoadjuvant chemotherapy and interval debulking sets out how that choice is made.
Ovarian tumours are several different diseases sharing an address. Borderline tumours are not invasive cancer and are often managed with surgery alone. Low-grade serous cancer behaves quite differently from high-grade serous and responds differently to chemotherapy. Clear cell, mucinous and endometrioid cancers each have their own pattern.
So if a report reads borderline versus invasive, low-grade versus high-grade, or carries the word possible anywhere near the diagnosis, a specialist re-reading of the slides is the correct next step before a treatment plan is built on top of it. A review that begins anywhere other than the pathology is reviewing the wrong thing.
This assessment is genuinely difficult and it is not always final. Whether a complete cytoreduction is achievable depends on where the disease sits, how experienced the surgical team is, and how well a woman would tolerate a long operation — and it can change once chemotherapy has reduced the disease burden.
So the useful question is not only whether surgery is possible today, but whether it might become possible after a few cycles of chemotherapy, and who would need to be in the room for it. A team that regularly deals with advanced ovarian disease answers that better than a single opinion can.
This is the most common genuine gap. BRCA and homologous recombination deficiency status influence whether maintenance therapy is likely to help, so the result is not academic — it feeds directly into what happens after chemotherapy finishes. Germline results also matter to sisters, daughters and mothers, who can act on the information long before any symptom appears.
Testing is worth arranging early rather than at the end of chemotherapy, because the result is needed at the point maintenance is decided. If it has not been raised at all, that alone is a reasonable prompt for a review.
The end of chemotherapy is a decision point, not a finish line. For many women with advanced disease there is a maintenance phase — PARP-inhibitor-class treatment, anti-angiogenic treatment, or both in combination — and the choice is made from stage, how the disease responded, the completeness of surgery, and BRCA or HRD status.
Because the window to start is defined, this is a poor moment to discover the conversation never happened. If your last few cycles are approaching and nobody has explained what comes next, ask now rather than at the final cycle.
Recurrence reopens every question. How long the interval since the last platinum-based chemotherapy has been shapes what is likely to work next; whether further surgery helps is a genuine judgement call rather than a settled rule; and clinical-trial options are worth asking about explicitly at this stage.
There is usually more time here than it feels like there is. A recurrence rarely demands a decision the same week, and it is a reasonable point to have the whole file read again from the beginning by someone who has not seen it before.
Sometimes that assessment is right, and an honest review will say so. But it should be a conclusion reached after the pathology, the imaging and the full treatment history have been read, and after the reader has considered whether an untried line of treatment or a trial exists.
Even where no further disease-directed treatment is appropriate, a review still has something to offer: proper symptom control, nutrition support and psychological support change how the months ahead are lived. A second opinion that ends in that conversation has not failed.
Read your own reports against this list. A blank is not evidence of a mistake — some are answered later in the pathway — but a file with several gaps is one worth having read properly.
Not just “ovarian cancer”. The histopathology should name the subtype and, for serous tumours, the grade. Everything after this is built on it.
A stage with its letter, such as IIIC. If your file has no stage recorded, the plan built on it cannot be assessed by anyone reading it.
If you have had surgery, the operation note should say whether disease was completely removed and, if not, how much remained. This drives what comes next.
Either results, or a stated plan and a date for testing. Discovering at the end of chemotherapy that it was never sent costs weeks.
The number of cycles intended, the interval between them, and what happens at the end of them. “We will see” is not a plan.
A record that the case was discussed by a group — medical, surgical and radiation oncology together — rather than decided by one clinician alone.
Take everything with you: the biopsy or surgical histopathology report, the paraffin blocks or slides if you can obtain them, all scan images on disc rather than the reports alone, blood results including CA-125, the operation note, and a written list of every treatment given with its dates. A reviewer working from photographs of reports on a phone is working with less than half the file.
A 45-minute consultation, a re-reading of your pathology and imaging, and a tumour-board discussion where the case warrants one. If the plan you already have is the right plan, we will say so plainly and send you back to your treating team.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed, no cost for the first consultation, and no obligation to move your care. Most reviews end in agreement — which is a useful answer, not a wasted trip.
A proper review is not a five-minute glance at a discharge summary. It is a sequence, and most of the useful part happens before anyone gives you an answer.
Histopathology report, blocks or slides where they can be released, scan images on disc, blood results including CA-125, the operation note if you have had surgery, and dates of every treatment given. Records held at another hospital are yours to request, and the staff there are used to being asked for them.
Review starts with the tissue, because subtype and grade sit underneath every later decision. Where the original report is ambiguous, or where borderline and invasive disease are hard to separate, the slides matter more than the report describing them.
Scans are read again to map where disease actually sits, which is what determines whether a complete cytoreduction is realistic and whether chemotherapy before surgery is the better sequence. The stage recorded in the file is checked against the images rather than accepted.
Unhurried, and long enough for the history and for your questions. Bring the person who has been at every appointment with you — what they remember about response, side effects and timing is often what changes a reading of the file.
Cases that raise a real question are put to a multidisciplinary group rather than answered by one clinician. That is the difference between a second opinion and simply a second individual, and it is where most disagreements with the original plan get resolved one way or the other.
You leave with the reasoning in writing, not just a verbal impression — what was reviewed, what is agreed, what differs and why. That document is yours, and it is written to be read by your existing treating team as much as by you.
Where the review agrees with your current plan, that is the report we write, and you go back to your existing team with it. A second opinion is not a recruitment exercise.
Six parts of the file, what a reviewer is actually looking for in each, and the decision it feeds. Most reviews change nothing in any row — the value lies in knowing that rather than assuming it.
| What is reviewed | What the reviewer looks for | What it can change |
|---|---|---|
| Histopathology | Subtype, grade, and whether a tumour is borderline or invasive. Ambiguity in the original report is the trigger for re-reading slides. | Whether chemotherapy is needed at all, and which treatment approach fits the subtype. |
| Imaging | Where disease actually sits, and whether the recorded stage matches the images. | Whether complete cytoreduction is realistic, and whether chemotherapy should come first. |
| Staging | That a FIGO stage is stated, with its letter, and that it follows from the pathology and imaging together. | The intent of treatment, and how much of the plan is fixed rather than still open. |
| Surgical record | Whether disease was completely removed, what remained, and who performed the procedure. | Whether further surgery has a role, and what maintenance is appropriate afterwards. |
| Systemic therapy plan | Cycles intended, intervals, response assessment, and what is planned for the end of chemotherapy. | Whether a maintenance phase is offered, and when that decision has to be made. |
| Genetic and genomic testing | Whether BRCA germline and tumour testing has been done, and HRD status where it is relevant. | Maintenance choices, and testing for sisters, daughters and mothers. |
*Surgery, HIPEC and intraperitoneal chemotherapy are delivered at specialist partner centres and may be billed there. A CION review can advise on the surgical decision and coordinate the referral; the operation itself is not performed in-house.
The first consultation at CION is free and runs to about 45 minutes, and where you bring your reports it comes with a written second opinion rather than a verbal impression at the door. Cases that raise a real question go to a tumour board — medical, surgical and radiation oncology reading the same file together — which is the part of a review that one extra individual opinion cannot reproduce.
What CION does directly is worth stating plainly, because it decides what a review can follow through on. Chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support, survivorship and follow-up are delivered in-house across 35+ centres in Telangana and Andhra Pradesh. Debulking and other gynaecologic-oncology surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist partner centres and may be billed there. We would rather you knew that at the first appointment than discovered it at the third.
You are not committing to anything by asking. Most reviews confirm the existing plan, and when they do we write that down and you take it back to the team already treating you. Where a review does differ, you will be told what differs and why, in language you can put in front of your current doctor. If you want to know who would be reading your file, our ovarian cancer specialists in Hyderabad are listed with their qualifications.
Unhurried, with a specialist, and long enough to read the whole file rather than the discharge summary. A written opinion follows where you bring reports.
A multidisciplinary group reads the case together. A second opinion from a team is a different thing from a second opinion from one more individual.
Chemotherapy, maintenance, genetic counselling and BRCA/HRD testing at CION. Surgery, HIPEC and PET-CT are coordinated at partner centres and billed there.
If a review does lead to treatment with us, chemotherapy and follow-up can usually run near where you live rather than requiring repeat trips to one city hospital.
It should not, and in cancer care it rarely does. Expert review of pathology and imaging is a normal part of the pathway rather than a challenge to anyone, and most oncologists would want a review for their own family. You do not need permission and you do not need to explain yourself, although telling your team means the records reach the reviewer faster. If a doctor reacts badly to being asked, that is information about the doctor rather than about the question. In practice the commonest outcome is that the reviewer agrees, writes that down, and you go back to the same team with more confidence than you had before.
Usually by days rather than weeks, and most of that time goes on gathering records rather than waiting for an appointment. Ovarian cancer is serious but it is very rarely a same-week emergency, and the decisions a review affects most, particularly the surgical one, are precisely the decisions that are hard to undo once taken. The exception is a woman who is acutely unwell, with a bowel obstruction or breathlessness from fluid, where stabilising treatment comes first and the review follows it. If you are worried about timing, request the review and start collecting the file on the same day.
The complete histopathology report, and the paraffin blocks or slides if the original laboratory will release them. All scan images on disc, not only the typed reports, because a reviewer needs to look at the pictures. Blood results including CA-125, with their dates. The operation note if you have had surgery, which should state what was removed and what remained. A written list of every treatment given, with dates and how you tolerated it. Any genetic test results. Finally, bring the person who has attended appointments with you, because what they remember about how you responded often fills the gaps the paperwork leaves.
The diagnosis of cancer itself rarely changes. What changes more often is its detail, and the detail drives the treatment. A tumour called borderline rather than invasive is managed very differently. Low-grade and high-grade serous cancers respond differently to chemotherapy. Clear cell, mucinous and endometrioid cancers each behave in their own way. The recorded stage can also shift once the imaging is read against the pathology. This is why a proper review begins with the tissue and the scans rather than with the treatment plan: correcting the foundation is what changes the building standing on it.
No. A second opinion is a reading of your file, not a transfer of care, and there is no obligation to move anything. Many women take the written opinion back to their original team and carry on exactly where they were, which is a perfectly good use of a review. Where the reviewer does suggest something different, the two teams can usually discuss it directly, and plenty of plans end up adjusted rather than replaced. Practical factors count too: how far you can reasonably travel for repeated chemotherapy cycles is a legitimate part of the decision, not a lesser one.
That depends less on the calendar than on which decision is still open. Once an operation has been performed it cannot be redone, so a review at that point comments rather than changes. But the pathway keeps producing new decision points: what happens at the end of chemotherapy, whether maintenance therapy is offered, what to do at recurrence, and whether further surgery has a role. Each of those is a fresh opportunity for a review to matter. So mid-treatment is not too late. It simply means the review should be aimed at the next decision rather than the last one.
The first consultation is free and runs to about 45 minutes, and it comes with a written second opinion when you bring your reports. CION delivers medical oncology for ovarian cancer in-house, which covers chemotherapy and maintenance treatment across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling and BRCA and HRD testing. Debulking and other gynaecologic-oncology surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered later. Every case that raises a real question is reviewed at a tumour board.